• Nefiracetam (DM 9384) is a pyrrolidone derivative with potential for use in patients with dementia secondary to cerebrovascular disorders or Alzheimer’s disease.
• It is thought to act by normalising dysfunctional acetylcholine, γ-aminobutyric acid (GABA) and possibly monoamine neurotransmitter systems, but it may also facilitate NIL-type calcium channel opening.
• Nefiracetam for 2 to 12 months improved cognitive function and psychiatric symptoms in patients with dementia due to cerebrovascular disorders.
• Nefiracetam was at least as effective as idebenone and was superior to placebo in patients with cerebrovascular dementia in large double-blind 8-week trials.
• Adverse events as reported in clinical trials are infrequent and are mainly gastrointestinal in nature.
Dementia Adis International Limited Idebenone Cerebrovascular Disorder Aniracetam
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Watabe S, Yamaguchi H, Ashida S-I. DM-9384, a new cognition enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex. Eur J Pharmacol 1993; 238: 303–9PubMedCrossRefGoogle Scholar
Tanaka S, Watabe S, Kakihata K, et al. Effects of the new cognition-enhancing agent nefiracetam in rats with cerebral embolism. Arzneimittel Forschung 1992; 42: 1274–8PubMedGoogle Scholar
Nabeshima T, Noda Y, Tohyama K, et al. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 1990; 178: 143–9PubMedCrossRefGoogle Scholar
Hiramatsu M, Koide T, Ishihara S-i, et al. Involvement of the cholinergic system in the effects of nefiracetam (DM-9384) on carbon monoxide (CO)-induced acute and delayed amnesia. Eur J Pharmacol 1992; 216: 279–85PubMedCrossRefGoogle Scholar
Kawajiri S, Taniguchi K, Sakurai T, et al. Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat. J Neural Transm Gen Sect 1994; 98: 15–22PubMedCrossRefGoogle Scholar
Abe E, Murai S, Saito H, et al. Effects of nefiracetam on deficits in active avpidance response and hippocampal cholinergic and monoaminergic dysfunctions induced by AF64A in mice. J Neural Transm Gen Sect 1994; 95(3): 179–93PubMedCrossRefGoogle Scholar
Nabeshima T, Tohyama K, Murase K, et al. Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and Muscarinic receptors induced by cycloheximide. J Pharmacol Exp Ther 1991; 257: 271–5PubMedGoogle Scholar
Abe E, Murai S, Saito H, et al. Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice. J Neural Transm Gen Sect 1992; 90(2): 125–36PubMedCrossRefGoogle Scholar
Luthman J, Lindqvist E, Kojima H, et al. Effects of nefiracetam (DM-9384), a pyrrolidone derivative, on brain monoamine systems. Arch Int Pharmacodyn Ther 1994; 328: 125–44PubMedGoogle Scholar
Watabe S, Taniguchi K, Kojima H. Improvement of impaired brain monoamine metabolism by the cognition-enhancing agent nefiracetam after microsphere-induced cerebral embolism in rats. Arzneimittel Forschung 1994; 44(2A): 195–8PubMedGoogle Scholar
Yoshii M, Watabe S. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells. Brain Res 1994; 642: 123–31PubMedCrossRefGoogle Scholar
Yamada K, Nakayama S, Shiotani T, et al. Possible involvement of the activation of voltage-sensitive calcium channels in the ameliorating effects of nefiracetam on scopolamine-induced impairment of performance in a passive avoidance task. J Pharmacol Exp Ther 1994; 270: 881–92PubMedGoogle Scholar
Sakurai T, Ojima H, Yamasaki T, et al. Effects of N-(2,6-dimethylphenyl)-2-(2-oxo-1 -pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats. Jpn J Pharmacol 1989; 50: 47–53PubMedCrossRefGoogle Scholar
Nabeshima T, Nakayama S, Ichihara K, et al. Effects of nefiracetam on drug-induced impairment of latent learning in mice in a water finding task. Eur J Pharmacol 1994; 255: 57–65PubMedCrossRefGoogle Scholar
Nabeshima T, Tohyama K, Kameyama T. Effects of DM-9384, a pyrrolidone derivative, on alcohol- and chlordiazepoxide-induced amnesia in mice. Pharmacol Biochem Behav 1990; 36: 233–6PubMedCrossRefGoogle Scholar
Sakurai T, Hatanaka S, Tanaka S, et al. Protective effect of DM-9384, a novel pyrrolidone derivative, against experimental cerebral anoxia. Jpn J Pharmacol 1990; 54: 33–43PubMedCrossRefGoogle Scholar
Woodruff-Pak DS, Li Y-T. Nefiracetam (DM-9384): effect on eyeblink classical conditioning in older rabbits. Psychopharmacology 1994; 114: 200–8PubMedCrossRefGoogle Scholar
Murasaki M, Inami M, Ishigooka J, et al. Phase I study on DM-9384 (nefiracetam) [in Japanese]. Yakuri to Chiryo 1994; 22: 3539–87Google Scholar
Ogura C, Uema T. Effects of nefiracetam (DM-9384) on psychiatric symptoms and event-related potentials in the patients with dementia [in Japanese]. Yakuri to Chiryo 1994; 22: 3625–43Google Scholar
Hirata K, Katayama S, Yamazaki K, et al. Electric field distribution of event-related potentials in stroke patients. Brain Topography 1996; 8(3): 279–84PubMedCrossRefGoogle Scholar
Sudo K, Hashimoto K, Fujimaki Y, et al. Disposition and metabolism of nefiracetam, a new nootropic agent, in the rat, dog and monkey. Yakuri to Chiryo 1994; 22: 3441–52Google Scholar
Fujimaki Y, Sudo K, Hakusui H, et al. Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers. J Pharm Pharmacol 1992; 44: 750–4PubMedCrossRefGoogle Scholar
Fujimaki Y, Sudo K, Hakusui H. Pharmacokinetics of nefiracetam and 3 metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring. Xenobiotica 1993; 23: 61–70PubMedCrossRefGoogle Scholar
Ohtomo E, Kogure K, Hirai S, et al. Clinical utility of DM-9384 (nefiracetam) in the treatment of cerebrovascular disorders: dose finding study by double-blind method [in Japanese]. Rinsho Iyaku 1994; 10(7): 1507–47Google Scholar
Kobayashi T, Ikeda M, Orishige T, et al. Investigation of DM-9384 (nefiracetam) in a long-term treatment of patients with after-effect of cerebrovascular disorders [in Japanese]. Yakuri to Chiryo 1994; 22: 3645–59Google Scholar
Hasegawa T, Shigeno K, Hirata Y, et al. Clinical evaluation of DM-9384 (nefiracetam) in a long-term treatment of patients with sequela of cerebrovascular disorders [in Japanese]. Rinsho Iyaku 1994; 10(9): 2087–106Google Scholar
Ohtomo E, Kogure K, Hirai S, et al. Clinical efficacy and safety of DM-9384 (nefiracetam) against after-effects following cerebrovascular disease (phase III study). A placebo-controlled double-blind comparative study [in Japanese]. Igaku Ayumi 1994; 170(9): 777–816Google Scholar
Ohtomo E, Kogure K, Hirai S, et al. Clinical utility of DM-9384 (nefiracetam) in patients with aftereffect following cerebrovascular disorders: a comparative double-blind study with idebenone [in Japanese]. Rinsho Iyaku 1994; 10(8): 1871–918Google Scholar
Fujikawa K, Akiyama Y, Takayama S. Drug dependence study of the new cognition-enhancing agent nefiracetam in rats. Arzneimittel Forschung 1994; 44(2A): 243–7PubMedGoogle Scholar